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Background: The analysis aimed to examine the impact of pulmonary exacerbations (PEs) and lung function on
generic measures of HRQL in patients with cystic fibrosis (CF) using trial-based data.
Methods: In a 48-week randomized, placebo-controlled study of ivacaftor in patients ≥12 years with CF and a
G551D-CFTR mutation the relationship between PEs, PE-related hospitalizations and percent predicted forced
expiratory volume in one second (ppFEV1) with EQ-5D measures (index and visual analog scale [VAS]) was examined in
post-hoc analyses. Multivariate mixed-effects models were employed to describe the association of PEs, PE-related
hospitalizations, and ppFEV1 on EQ-5D measures.
Results: One hundred sixty one patients (age: mean 25.5 [SD 9.5] years; baseline ppFEV1: 63.6 [16.4]) contributed 1,214
observations (ppFEV1: no lung dysfunction [n = 157], mild [n = 419], moderate [n = 572], severe [n = 66]). Problems were
most frequently reported on pain/discomfort, anxiety/depression, and usual activities EQ-5D items. The mean (SE)
EQ-5D index nominally decreased (worsened) with worsening severity of lung dysfunction (P = 0.070): 0.931 (0.023);
mild: 0.923 (0.021); moderate: 0.904 (0.018); severe: 0.870 (0.020). 146 PEs were experienced by 72 patients, including 52
PEs (35.6 %) that required hospitalization. Mean EQ-5D index and VAS scores were lowest (worst) within 1 week (before
or after PE start) for PEs requiring hospitalization. Pulmonary exacerbations, PE-related hospitalizations, and ppFEV1
were significant predictors of EQ-5D index and VAS.
Conclusions: In a clinical study of patients with CF (≥12 years of age and a G551D-CFTR mutation), PEs, primarily those
requiring hospitalization, were associated with low EQ-5D index and VAS scores. The impact of ppFEV1 was relatively
smaller. Reducing PEs, in particular those requiring hospitalization, would likely improve HRQL among these patients.
Trial registration: ClinicalTrials.gov, NCT00909532; URL: clinicaltrials.gov, May 26, 2009
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Health-related quality of life (HRQL) is an increasingly
important multi-dimensional clinical outcome assessment
which provides insights into the patient’s experience of
disease burden and the effects of medical interventions.
Measures of HRQL are patient-reported and can be
generic or disease-specific [1]. Disease-specific measures
may be more sensitive to some of the symptoms experi-
enced by patients but generic measures permit uniform* Correspondence: csolem@pharmerit.com
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necessary to aid decision making in evaluating the value
of new treatments. As the landscape of therapies for cystic
fibrosis (CF) expands, it is important to characterize the
relationship between clinical and physiologic measures of
disease and generic measures of HRQL.
Cystic fibrosis is an inherited, rare autosomal recessive
disease that results in chronically debilitating morbidities
and high premature mortality [2]. CF disease affects mul-
tiple organs in the body including the lung, pancreas,
intestinal and biliary tracts, sweat glands and the repro-
ductive system [3]. Patients with CF typically experience
progressive loss of lung function ultimately resulting inis distributed under the terms of the Creative Commons Attribution 4.0
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affecting CF disease trajectory is the occurrence of pul-
monary exacerbations (PEs), which require acute med-
ical care and often hospitalization. Avoiding PEs is a
foremost goal of CF treatment since exacerbation fre-
quency is associated with lung function decline, greater
likelihood of subsequent exacerbations and increased mor-
tality [4]. Pulmonary exacerbations, particularly those that
are severe, have been reported to impact HRQL [5–8].
Lung function as measured by forced expiratory volume
(FEV1) is an outcome measure in clinical studies of CF
therapies and has been shown to be related to patient’s
survival and HRQL in cross-sectional and longitudinal
studies [8, 9].
Research to date has reported mixed degrees of as-
sociations between several CF physiologic and clinical
measures such as FEV1 and PEs, and generic and
disease-specific HRQL measures (e.g. Cystic Fibrosis
Questionnaire-Revised [CFQ-R] scores) [5–8] of CF
symptoms and HRQL. Previous studies of patients with
CF have reported utilities derived using time tradeoff
[7, 10–12] and standard gamble [7, 13, 14] direct elicit-
ation methods, and generic indirect measures including
the health utilities index (HUI2 and HUI3) [7, 14, 15],
and the EuroQol EQ-5D [6, 16, 17] with varying results.
Within CF there has been evidence of potential ceiling
effects of generic measures such as the EQ-5D and in-
sensitivity particularly to FEV1. While some of these
studies have independently assessed the impact of lung
function and PEs on generic measures of HRQL in CF,
no studies to date have analyzed both of these key dis-
ease elements within the same model. In order to better
assess this, the aim of this analysis is to examine the
impact of PEs and lung function on generic HRQL as
assessed by the EQ-5D-3 L questionnaire in patients
aged 12 years and older with CF and a G551D mutation




This analysis used data from a 48-week, Phase 3, inter-
national, multicenter, randomized, double-blind, placebo-
controlled study (STRIVE) which was designed to evaluate
the efficacy and safety of ivacaftor in patients aged 12 years
and older with CF who had a G551D mutation on at least
1 CFTR allele [18]. Patients were included if they had an
FEV1 of 40 to 90 % (inclusive) of the predicted normal
value for age-, gender-, and height-matched persons at
screening (ppFEV1). As reported in Ramsey et al. [18],
“subjects were excluded if they had other illnesses that
confounded the study results; ongoing illness; a pulmon-
ary exacerbation or changes in therapy (including antibi-
otics) for pulmonary disease within 4 weeks before firstdose of study drug; abnormal liver function tests, de-
fined as 3 or more LFT parameters >3 times the upper
limit of normal; or abnormal renal function tests. Subjects
were also excluded if they had a history of prolonged QT/
QTc interval; history of solid organ or hematological
transplantation; colonization with organisms associated
with a more rapid decline in pulmonary status (e.g., B.
cenocepacia, B. dolosa, and M. abcessus); concomitant
use of any inhibitors or inducers of CYP3A4; or use of
inhaled hypertonic saline treatment. Subjects were re-
quired to stop inhaled hypertonic saline treatment for
at least 4 weeks prior to Day 1 (first dose of study
drug)”. Study assessments were conducted at baseline,
day 15, week 8, and every 8 weeks thereafter through
48 weeks.
Study measures
Health-related quality of life
The EQ-5D-3 L [19] is a generic measure of HRQL that
includes two components: a descriptive profile and a
visual analogue scale (VAS). The descriptive profile in-
cludes five single-item dimensions (mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression),
each with 3 levels of response (no problems, some prob-
lems, and extreme problems) that can be combined into a
single score (index) which summarizes health status (i.e.,
utility) and is anchored at 0 (=death) and 1 (=perfect
health). The index is calculated by an algorithm using
patients’ responses to the EQ-5D descriptive profile and
preference weights for different health states ascertained
from the general population of a country (herein, using
values for the United Kingdom [UK]) [20].
The EQ-5D VAS records the respondent’s self-rated
health on a 20 cm vertical VAS with endpoints labeled
“the best health you can imagine” and “the worst health
you can imagine.” [19]. This information can be used as
a quantitative measure of health status as rated by the
individual respondents.
Lung function
In the STRIVE study, ppFEV1 was the primary outcome
measure. In our analyses, we characterize lung dysfunction
respectively as: (1) no lung dysfunction (ppFEV1 ≥ 90 %),
mild (70 ≤ ppFEV1 < 90 %), moderate (40 ≤ ppFEV1 < 70 %),
and severe (FEV1 < 40 %); (2) deciles of ppFEV1; and (3)
ppFEV1 treated as a continuous variable in multivariate
analyses. Note that while patients were required to have at
least mild lung dysfunction at entry to the trial, it was
possible for patients to improve and have observations
with no lung dysfunction at later points within the trial.
Pulmonary exacerbations
In the clinical study, PEs were defined as a change in anti-
biotic therapy for ≥4 of 12 signs or pre-defined sino-
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creased hemoptysis; increased cough; increased dys-
pnea; malaise, fatigue, or lethargy; temperature above
38 °C; anorexia or weight loss; sinus pain or tenderness;
change in sinus discharge; change in physical examination
of the chest; decrease in pulmonary function by 10 %;
radiographic changes indicative of pulmonary infection).
PE start and end dates and information on whether PEs
required hospitalization or not was also collected.
Statistical analysis
EQ-5D measures were exploratory endpoints in the
STRIVE clinical trial and their analyses were not pre-
specified therefore no statistical correction for multiplicity
was undertaken. Accordingly, three sets of post-hoc ana-
lyses were subsequently conducted using trial-based data
as described below. Analyses were undertaken using SAS/
STAT® software, Versions 9.3 and 9.4 of the SAS System
for Windows (Cary, NC, USA).
1) Relationship between EQ-5D measures and ppFEV1
Mean values and 95 % confidence intervals for
EQ-5D index and VAS scores were calculated
using all observations across all study assessments
and treatments and stratified by deciles of ppFEV1,
and categories of lung dysfunction as described
previously The proportions of patients with maximum
value of EQ-5D index (=1) and VAS score (=100)
respectively were calculated to assess ceiling effects.
2) EQ-5D measures and ppFEV1 among patients who
experienced PEs
Data from patients who experienced at least one PE
were included in this analysis. The periods prior and
subsequent to the study defined PE start date were
arbitrarily specified and grouped into pre-PE periods
(>8 weeks, >4–8 weeks and > 1–4 weeks) and post-PE
periods (>8 weeks, >4–8 weeks, > 1–4 weeks)
respectively. The one-week pre- and post-PE start
date constituted the reference category (i.e., “PE
start period”). Mean (SD) duration of PEs was also
calculated based on study defined PE start and end
dates, overall and for patients for whom PEs
required hospitalization and for those for whom
they did not respectively (unadjusted).
Observations were visually graphed and overlaid
with local regressions (LOESS) to depict the EQ-5D
index and VAS scores over time respectively.
Mixed-effects models for repeated measures
(MMRM) were employed to generate (least squares
[LS]) mean values for each period controlling for
baseline ppFEV1, age, sex, baseline body mass index
(BMI), baseline sweat chloride, history of pancreatic
insufficiency and baseline use of cycling antibiotics,
and repeated observations. Models were also usedto evaluate differences in EQ-5D index, VAS scores,
and ppFEV1 between pre- and post-PE start periods
and the reference period. A subgroup analysis was
also conducted for patients for whom the absolute
ppFEV1 value did not decline by 10 or more
percentage points (from randomization to the
closest ppFEV1 assessment) prior to the PE start date.
3) Association of PEs, ppFEV1 and EQ-5D measures
Data from all patients (those who experienced PEs
during the clinical study and those who did not)
were included in this analysis. For patients who
experienced one or more PEs, EQ-5D index, VAS
scores and ppFEV1 between PE start and end dates
(inclusive of those dates) were considered related to
a PE. Observations that did not occur during a PE
window were not considered PE-related. Multivariate
(MMRM) analyses were undertaken to examine the
association of experiencing a PE (requiring and not
requiring hospitalization), and ppFEV1 (with linear
and quadratic terms) with the EQ-5D measures as
dependent variables. As a sensitivity analysis, regression
models were also developed using US, Europe,
Netherlands, and Belgium EQ-5D index value sets
(i.e., preference weights), [21–23] as well as for VAS
scores that were transformed into a health-state utility
value using a previously reported equation [24].
Ethics
The STRIVE clinical trial (“A Phase 3, Randomized,
Double-Blind, Placebo-Controlled, Parallel-Group Study
to Evaluate the Efficacy and Safety of VX-770 in Subjects
with Cystic Fibrosis and the G551D Mutation”) protocol
was reviewed and approved by the institutional review
board at each participating center, and each subject pro-
vided written informed consent or written or oral assent.
Results
A total of 161 patients (age: mean [SD] 25.5 [9.5] years;
baseline ppFEV1: mean [SD] 63.6 [16.4]) contributed
1,214 sets of observations (EQ-5D measures and ppFEV1)
over 48 weeks. Of the 1,214 ppFEV1 assessments (no lung
dysfunction [n = 157], mild [n = 149], moderate [n = 572],
and severe [n = 66]), all but 12 occurred on the same day
as the EQ-5D measurements. Over the course of the
study, patients most frequently reported problems with
pain/ discomfort (20.2 %), followed by anxiety/ depression
(16.4 %), and usual activities (14.1 %). The EQ-5D index
was at its ceiling (=1) for 67.5 % (no lung dysfunction:
80.9 %; mild: 73.3 %; moderate: 62.1 %; severe: 45.5 %) of
observations whereas the EQ-5D VAS was at the ceiling
(VAS = 100) for 5.6 % (no lung dysfunction: 15.9 %; mild:
6.9 %; moderate: 2.4 %; severe: 0.0 %) of observations.
A total of 146 PEs were experienced by 72 (44.7 % of
total 161) patients, including 52 PEs (35.6 %) that
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(22.2) days for PEs requiring hospitalization and 20.6
(11.6) days for those not requiring hospitalization (11
PEs from 9 patients had missing PE end dates and were
excluded). The baseline characteristics of patients who
experienced a PE during the study and those who did
not are summarized in Table 1. Patients who did not ex-
perience a PE during the study had on average a higher
ppFEV1 at study initiation than those who experienced
one or more PEs. Patients who experienced a PE requir-
ing hospitalization were younger than those with a PE
not requiring hospitalization and the mean ppFEV1 at
study initiation did not differ between these two groups.EQ-5D measures and ppFEV1
Figure 1 shows EQ-5D index and VAS scores by ppFEV1
decile. VAS scores appeared to be more discriminating
of CF lung disease severity than the EQ-5D index. Within
MMRM models, the EQ-5D index (mean, [SE]) nominally
decreased (worsened) with increasing severity of lung dys-
function (P = 0.070): no lung dysfunction: 0.931 (0.023);
mild: 0.923 (0.021); moderate: 0.904 (0.018); severe: 0.870
(0.020). Mean (SE) VAS scores followed a similar trend
and were significantly different (P < 0.001) across ppFEV1
categories: no lung dysfunction: 85.2 (2.0); mild: 82.3 (1.8);
moderate: 76.8 (1.6); severe: 73.3 (1.8).EQ-5D measures and ppFEV1 by time since PE start
EQ-5D index and VAS scores over time in relation to PE
start are shown in Figs. 2 and 3 respectively. Nominal
trends for declining (worsening) values in the pre- PE
start periods can be inferred from visual inspection of the
data (both index and VAS scores) suggesting detrimental
changes in health status and symptoms in advance of the
study defined PE start date, followed by a trend for
recovery.Table 1 Patient Characteristics at Baseline, by Pulmonary Exacerbati
No PE An
(n = 89) (n =
Age, Mean (SD) 25.5 (10.2) 25.
Female, N(%) 41 (46.1 %) 43
ppFEV1, Mean (SD) 65.8 (15.8) 60.
BMI, N(%)
Normal Weight 75 (84.3 %) 57
Obese 3 (3.4 %) 2 (
Overweight 9 (10.1 %) 8 (
Underweight 2 (2.3 %) 5 (
Sweat chloride, Mean (SD) 100.5 (9.5) 99.
History of pancreatic insufficiency, N(%) 81 (91.0 %) 68
Use of inhaled cycling antibiotic, N(%) 37 (41.6) 19For PEs that required hospitalization mean EQ-5D
index, VAS scores and ppFEV1 values were lowest (worst)
during the PE start period within MMRM (Table 2); mean
values for the EQ-5D and ppFEV1 measures are suggestive
of a trend towards recovery following the PE start period
although findings did not always reach statistical sig-
nificance (compared to the PE start period). A similar
pattern is suggested by findings for PEs that did not re-
quire hospitalization, but overall, results did not achieve
statistical significance. Findings from a subanalysis which
removed patients who had a ppFEV1 decline of 10 or
more percentage points at the observation nearest to the
PE start date were consistent with similar detrimental
impacts on the EQ-5D index (for PEs that required
hospitalization), suggesting that PEs affect HRQL beyond
the ppFEV1 decline alone (data not shown).
In examining Fig. 3, one might question the “peak” in
VAS scores for patients who experienced a PE requiring
hospitalization immediately prior to the PE start date. Of
the 6 observations that occurred within the 3 days prior
to exacerbation, 3 had VAS values that were > 90. Two
of these three assessments were provided by patients
with ppFEV1 < 70 % at the time of that visit; two add-
itional observations, from different patients, also had a
concurrent EQ-5D index < 1.
Mean ppFEV1 was significantly lower during the PE
start period as compared to the preceding and subsequent
periods in particular for PEs that required hospitalization.
Findings were similar for PEs that did not require
hospitalization but did not always reach statistical sig-
nificance when compared to the PE start period.
Between PE start and end dates, patients were most
likely to report problems for usual activities (53.6 % of ob-
servations), pain/discomfort (39.3 %) and mobility
(32.1 %) for PEs that required hospitalization. For PEs not
requiring hospitalization, the trend was similar but fewer
patients reported problems: 35.7 % for usual activities,ons During Study
y PE PE (No Hospitalization) PE (Hospitalization)
72) (n = 38) (n = 34)
4 (8.8) 28.3 (7.8) 22.0 (8.7)
(59.7 %) 20 (52.6 %) 23 (67.6 %)
8 (16.9) 60.9 (16.3) 60.6 (17.7)
(79.2 %) 28 (73.7 %) 29 (85.3 %)
2.8 %) 2 (5.3 %) 0 (0 %)
11.1 %) 6 (15.8 %) 2 (5.9 %)
6.9 %) 2 (5.3 %) 3 (8.8 %)
9 (11.3) 100 (11.4) 99.8 (11.2)
(94.4 %) 35 (92.1 %) 33 (97.1 %)
(26.4 %) 8 (21.1 %) 11 (32.4 %)
Fig. 1 Mean EQ-5D Index and VAS Scores by ppFEV1 (Unadjusted)
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and depression and mobility. Problems were reported on
at least one dimension of the EQ-5D for 52.4 % of obser-
vations for hospitalized and non-hospitalized PEs and for
31.5 % of observations that did not occur during a PE.
Association of PEs, ppFEV1 and EQ-5D measures
In multivariate analyses, PE and low ppFEV1 values were
significantly (P <0.05) associated with a lower (worse)
EQ-5D index (Table 3). When PEs were stratified by
hospitalization status, experiencing a PE requiring
hospitalization and low ppFEV1 at the observation time
were significant (p < 0.05) predictors of EQ-5D index.
PEs not requiring hospitalization had a negligible positive
effect (P = 0.965). In VAS models, PEs, PEs requiring
hospitalization, and low ppFEV1 were associated withFig. 2 EQ-5D Index by Time since PE Start and Hospitalizationlower (worse) VAS scores (Table 3). Interestingly PEs not
requiring hospitalization had a greater (negative) effect on
VAS scores as compared to PEs requiring hospitalization.
Conclusions did not change when applying US, Belgium,
Netherlands, European algorithms reflecting country-
specific preference weights and the VAS transformed
algorithm (Additional file 1).
Discussion
This analysis provides the first assessment of the impact
of both lung function and PEs on a generic HRQL meas-
ure in patients with CF. In post-hoc analyses of data
from a clinical study of patients with CF (≥12 years of
age and a G551D-CFTR mutation), PEs, primarily those
requiring hospitalization, were associated with lower
HRQL as measured by the EQ-5D index. Mean EQ-5D
Fig. 3 EQ-5D VAS Scores by Time since PE Start and Hospitalization
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after PE start) for PEs requiring hospitalization. Similar
findings were observed for ratings of health status as
measured by VAS scores for all PEs regardless of
whether they required hospitalization. Lung function
as measured by ppFEV1 was also on average lowest
(worst) within the one-week period before or after the
study defined PE start date regardless of whether PEsTable 2 EQ-5D index, VAS scores and ppFEV1 by time since Pulmon
EQ-5D Index
n LS Mean (SE)
PE Requiring Hospitalization
>8 weeks prior 162 0.904 (0.020)
>4–8 weeks prior 27 0.884 (0.030)
>1–4 weeks prior 20 0.905 (0.034)
Within 1 week of start: reference group 23 0.760 (0.033)
>1–4 weeks post 15 0.841 (0.039)
>4–8 weeks post 29 0.847 (0.030)
>8 weeks post 121 0.856 (0.021)
PE Not Requiring Hospitalization
>8 weeks prior 305a 0.883 (0.016)
>4–8 weeks prior 54 0.912 (0.024)
>1–4 weeks prior 36 0.876 (0.029)
Within 1 week of start: reference group 38 0.876 (0.027)
>1–4 weeks post 33 0.916 (0.029)
>4–8 weeks post 47 0.849 (0.025)
>8 weeks post 210 0.857 (0.017)
Abbreviations: ppFEV1 percent predicted forced expiratory volume in 1 s, VAS visual
aN = 304 observations for ppFEV1required hospitalization or not. In multivariate analyses,
experience of any PEs, PEs requiring hospitalization and
low ppFEV1 were identified as independent negative pre-
dictors of EQ-5D index and VAS scores.
Our study findings are consistent with those reported by
others [5, 6]. A prior meta-analysis has identified PEs and
ppFEV1 as predictors of disease-specific HRQL and symp-
toms as measured by Cystic Fibrosis Questionnaire-ary Exacerbation Start
EQ-5D VAS ppFEV1
p-value LS Mean (SE) p-value LS Mean (SE) p-value
<0.001 72.8 (2.1) 0.015 60.9 (2.1) 0.043
0.001 73.3 (3.1) 0.038 60.1 (2.5) 0.226
<0.001 73.8 (3.5) 0.046 64.7 (2.6) 0.002
- 65.3 (3.4) - 57.6 (2.5) -
0.084 74.5 (4.0) 0.053 65.5 (2.8) 0.002
0.022 72.7 (3.1) 0.052 63.4 (2.4) 0.004
0.002 72.0 (2.2) 0.034 62.7 (2.2) 0.003
0.787 72.1 (1.5) 0.021 59.3 (1.7) 0.029
0.252 73.3 (1.9) 0.014 58.3 (1.8) 0.336
0.988 72.5 (2.2) 0.071 60.6 (1.9) 0.015
- 68.0 (2.1) - 57.1 (1.9) -
0.276 70.6 (2.2) 0.295 57.6 (1.9) 0.753
0.396 71.9 (2.0) 0.082 57.5 (1.8) 0.748
0.470 70.2 (1.5) 0.233 58.7 (1.7) 0.115
analog scale score, LS least-squares
Table 3 Association of ppFEV1 and Pulmonary Exacerbations with EQ-5D Index and VAS
Parameter Model 1: ppFEV1 Only Model 2: ppFEV1 + Any PE Model 3: ppFEV1 + PE Type
EQ-5D Index
Intercept 0.670 (0.068)** 0.678 (0.067)** 0.686 (0.067)**
ppFEV1 0.580 (0.193)** 0.561 (0.193)* 0.535 (0.193)*
ppFEV1 squared −0.305 (0.135)** −0.294 (0.135)* −0.274 (0.135)*
Any PE – −0.026 (0.013)* –
PE (Hospitalization) – – −0.070 (0.020)*
PE (No Hospitalization) – – 0.001 (0.016)
EQ-5D VAS
Intercept 57.79 (2.38)** 58.46 (2.36)** 58.48 (2.36)**
ppFEV1 32.14 (3.23)** 31.52 (3.21)** 31.49 (3.21)**
Any PE – −4.4 (1.08)** –
PE (Hospitalization) – – −3.82 (1.69)*
PE (No Hospitalization) – – −4.75 (1.34)**
Abbreviations: PE pulmonary exacerbation, ppFEV1 percent predicted forced expiratory volume in 1 second, VAS visual analog scale
*p < 0.05 **p < 0.001
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data from pediatric and adult patients with CF treated in a
US Midwestern CF center, PEs were reported to have a
profound negative impact on physical and psychosocial
HRQL using the generic Short-Form (SF)-36 and the
Child Health Questionnaire; the impact of ppFEV1 was re-
ported to be relatively small compared to the impact of
PEs [8]. In another study conducted in five UK CF centers,
adolescent patients with CF and chronic Pseudomona aer-
uginosa infection who experienced PEs that required
hospitalization reported poorer HRQL using the EQ-5D
index as well as worse VAS scores compared to those with
chronic infection and milder PEs (i.e., not requiring
hospitalization) [6].
In our analyses, ceiling effects were high, particularly for
the EQ-5D index and in patients with no lung dysfunction
or mild lung dysfunction as well as among those with less
severe disease (i.e., patients who did not experience PEs).
Mixed results have been reported by others regarding the
association between physiologic measures of pulmonary
disease and CF, particularly ppFEV1, nutritional indices
and HRQL [8, 25–27]. Patients with the most severe dis-
ease as measured by pulmonary function measures and
weight for height have been reported to rate their CF as
“above/well above average” compared to other patients
with CF whereas physician’s ratings of disease severity were
positively correlated with clinical findings [28]. Yi et al.’s
study of adolescents with CF that employed preference
elicitation methods (e.g., time tradeoff, standard gamble)
found that HRQL was poorly associated with lung function
[7]. In our subgroup analysis, HRQL impacts of PEs requir-
ing hospitalization were still apparent after exclusion of pa-
tients who did not experience a decline in absolute ppFEV1
of 10 percentage points or higher prior to the PE start date.In summary, our results are supportive of prior sug-
gestions that “the powerful association of HRQL with
exacerbations, and the weaker association with FEV1
percent predicted may imply that for patients with CF
and their families, HRQL may have less to do with how
severe one’s underlying disease is, and more to do with
the disruptive effect of exacerbations.” [8]. While this
may be more strongly observed for disease specific
measures, there is an important role for including and
assessing the impact of disease on generic measures,
which are frequently used for cross-condition compari-
sons. The STRIVE trial appropriately included the EQ-5D
as a generic measure of HRQL and the Cystic Fibrosis
Questionnaire- Revised which has been reported else-
where [29].
It should be noted that the EQ-5D index at the time
of study initiation was high (mean ≈ 0.93) leaving little
room for improvement with study treatments. There are
multiple possible explanations for these high values.
Among others, STRIVE study criteria excluded patients
with a history of any illness or condition that, in the
opinion of the investigator, could confound the results of
the study or pose an additional risk in administering
study drug to the patients, acute respiratory illness or PE
within four weeks of baseline, those with colonization
with selected microorganisms, and patients with any
“non-CF-related” illness within 2 prior weeks. High scores
have been also reported at the time of study initiation in
the TIGER clinical trial (Health State Utilities Index
[HUI] = 0.90, and 0.83 using a feeling thermometer similar
to the VAS) [15]. High values may also be explained by
patients’ adaptation and coping mechanisms leading to
acceptance of their chronic condition. From the physician’s
point of view, patients with CF and their close companions
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estimate self-care, and such perceptions often remain con-
stant over time even if the patient’s health is clinically
deteriorating [28]. Denial of physical symptoms as a pro-
tective means for psychosocial adaptation and emotional
resiliency are suggested strategies for living in the present
used by patients with chronic disease which may limit con-
sideration of the full impact of their condition when evalu-
ating health on a given day [15, 30–33].
While both EQ-5D and VAS are generic measures,
they provide complementary information; the use of the
EQ-5D index alone (a generic HQRL measure) may limit
characterization of disease burden and health gains in
patients with CF. The EQ-5D index is however, a neces-
sary generic HRQL (“health-state utility”) metric that is
typically required in cost-effectiveness evaluations of
new therapies [34]. In our analysis, the EQ-5D VAS meas-
ure showed greater ability to discriminate disease severity
(as measured by ppFEV1 and PEs respectively) than the
EQ-5D index. This broader range of response on the VAS
measure, as compared to the EQ-5D index, which has also
been reported by others [6], may point to health con-
structs or dimensions that may not be fully captured by
the EQ-5D questionnaire. Some dimensions of the EQ-
5D, particularly self-care, are less likely to be impacted
by CF; pain, discomfort, anxiety and depression have
been reported to be most affected in previous studies
[16, 35, 36] but others may not be well represented by
this generic HRQL measure. Use of disease-specific
measures (e.g., CFQ-R) alongside generic instruments,
per guidance, [1] should provide complementary assess-
ment of patient-reported symptoms and HRQL.
The current analysis does have a number of limitations.
EQ-5D measures were not assessed at the time of PE start
as this was not part of the original study design. Sample
size was small for ppFEV1 category <40 % and for some of
the PE-related analytical windows employed in our ana-
lyses. Patients in clinical practice may differ from those
participating in the STRIVE clinical trial and caution
should be used in generalization of study findings. Also,
the STRIVE clinical study included only patients with CF
and the G551D-CFTR mutation. Finally, the EQ-5D was
designed for use in populations 18 years of age or older,
[19] whereas this study included adolescent patients as
young as 12 years of age. However, it should be noted that
some previous research has indicated that as long as the
language and concepts used within the instrument are
understood, the EQ-5D may be used in adolescents (12–
18 years) with adequate functioning ([37] as cited in [38]).
Conclusion
In summary, in a clinical study of patients with CF
(≥12 years of age and a G551D-CFTR mutation), PEs,
primarily those requiring hospitalization, were associatedwith low EQ-5D index and VAS scores. The impact of
ppFEV1 was relatively smaller. Reducing PEs, in particu-
lar those requiring hospitalization, is likely to improve
HRQL among these patients.
Availability of data and materials
Supplemental data and materials are available upon
request.
Ethics approval and consent to participate
This was a secondary analysis of the STRIVE clinical
trial data. Please see original trial [18] for information
on ethics approval.
Additional file
Additional file 1: Mixed model parameter estimates in models
predicting EQ-5D utility values using US, European and Belgium EQ-5D
algorithms and VAS-transformed utilities. (DOCX 15 kb)
Abbreviations
BMI: body mass index; CF: cystic fibrosis; HRQL: health-related quality of life;
LOESS: non-parametric local regression smoothing; PE: pulmonary
exacerbation; ppFEV1: percent predicted forced expiratory volume in
1 second; VAS: visual analog scale.
Competing interests
This study was sponsored by Vertex Pharmaceuticals Incorporated, Boston,
Massachusetts. Brenda Castiglione is an employee of Vertex Pharmaceuticals
and owns stock or stock options of Vertex Pharmaceuticals. Caitlyn Solem,
and Marc Botteman are employees of Pharmerit International, a health-
services research consultancy that received fees for conducting analyses and
manuscript preparation. Sizhu Liu was an employee of Pharmerit Inter-
national and Montserrat Vera-Llonch was an employee of Vertex Pharmaceu-
ticals at the time the study was undertaken.
Authors’ contributions
C S, M V L; and M B contributed to study design and conceptualization. C S
and S L undertook data analysis. All authors contributed to data
interpretation, manuscript drafting, and approved the final manuscript.
Acknowledgements
We extend our deepest appreciation to the adolescents and adults with CF
who participated in the STRIVE study. The authors are grateful for the
analytical suggestions provided by Dr. Mark Higgins.
Author details
1Pharmerit International, 4350 East West Hwy, Suite 430, Bethesda, MD
20814, USA. 2Vertex Pharmaceuticals, 50 Northern Ave, Boston, MA 02210,
USA.
Received: 20 October 2015 Accepted: 7 April 2016
References
1. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing
health status and quality of life. Med Care. 1989;27(3 Suppl):S217-32. Review.
PubMed PMID: 2646490.
2. Sheppard MN, Nicholson AG. The pathology of cystic fibrosis. Curr Diagn
Pathol. 2002;8(1):50–9.
3. Boucher RC. Airway surface dehydration in cystic fibrosis: pathogenesis and
therapy. (0066–4219 (Print)).
4. de Boer K, Vandemheen KL, Tullis E, Doucette S, Fergusson D, Freitag A,
Paterson N, Jackson M, Lougheed MD, Kumar V, Aaron SD. Exacerbation
frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax.
Solem et al. Health and Quality of Life Outcomes  (2016) 14:63 Page 9 of 92011;66(8):680-5. doi:10.1136/thx.2011.161117. Epub 2011 Jun 15. PubMed
PMID: 21680566.
5. Habib AR, Manji J, Wilcox PG, Javer AR, Buxton JA, Quon BS. A systematic
review of factors associated with health-related quality of life in adolescents
and adults with cystic fibrosis. Ann Am Thorac Soc. 2015;12(3):420-8. doi:10.
1513/AnnalsATS.201408-393OC. Review. PubMed PMID: 25642976.
6. Bradley JM, Blume SW, Balp MM, Honeybourne D, Elborn JS. Quality of life
and healthcare utilisation in cystic fibrosis: a multicentre study. Eur Respir J.
2013;41(3):571–7.
7. Yi MS, Britto MT, Wilmott RW, Kotagal UR, Eckman MH, Nielson DW, et al.
Health values of adolescents with cystic fibrosis. J Pediatr. 2003;142(2):133–40.
8. Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J, Wilmott RW.
Impact of recent pulmonary exacerbations on quality of life in patients with
cystic fibrosis. Chest. 2002;121(1):64–72.
9. Taylor-Robinson D, Whitehead M, Diderichsen F, Olesen HV, Pressler T,
Smyth RL, et al. Understanding the natural progression in %FEV1 decline in
patients with cystic fibrosis: a longitudinal study. Thorax. 2012;67(10):860–6.
10. Busschbach JJ, Horikx PE, van den Bosch JM, Brutel de la Riviere A, de
Charro FT. Measuring the quality of life before and after bilateral lung
transplantation in patients with cystic fibrosis. Chest. 1994;105(3):911–7.
11. Rowley PT, Loader S, Kaplan RM. Prenatal screening for cystic fibrosis
carriers: an economic evaluation. Am J Hum Genet. 1998;63(4):1160–74.
12. Veenstra DL, Harris J, Gibson RL, Rosenfeld M, Burke W, Watts C.
Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss
in cystic fibrosis patients: potential impact on clinical, patient, and economic
outcomes. Genet Med. 2007;9(10):695–704.
13. Ramsey SD, Patrick DL, Albert RK, Larson EB, Wood DE, Raghu G. The cost-
effectiveness of lung transplantation. A pilot study. University of Washington
Medical Center Lung Transplant Study Group. Chest. 1995;108(6):1594–601.
14. Santana MJ, Feeny D, Ghosh S, Lien DC. Patient-reported outcome 2 years
after lung transplantation: does the underlying diagnosis matter? Patient
Relat Outcome Meas. 2012;3:79–84.
15. Dewitt EM, Grussemeyer CA, Friedman JY, Dinan MA, Lin L, Schulman KA,
et al. Resource use, costs, and utility estimates for patients with cystic
fibrosis with mild impairment in lung function: analysis of data collected
alongside a 48-week multicenter clinical trial. Value Health. 2012;15(2):277–83.
16. Connolly M, Johnson J, Brown NE, Montgomery M, Zuberbuhler P:
Development Of A Disease-Specific Health-Related Quality Of Life
Instrument For People With Cystic Fibrosis. In: Working Paper 00–11.
Edited by http://citeseerx.ist.psu.edu/viewdoc/download;
jsessionid=055FD26C437F1001EAC55AFAE214190D?doi=10.1.1.617.
8566&rep=rep1&type=pdf: Institute of Health Economics, Alberta, Canada.
17. S Acaster, B Pinder, J Osmond, C Mukuria. Mapping the Cystic Fibrosis
Questionnaire – Revised (CFQ-R) to a Preference Based Utility Index. 36th
European Cystic Fibrosis Society Conference 2013, June 12–15, 2013(Lisbon,
Portugal).
18. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, et al. A
CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N
Engl J Med. 2011;365(18):1663–72.
19. About EQ-5D [http://www.euroqol.org/about-eq-5d.html]
20. Dolan P. Modeling valuations for EuroQol health states. Med Care.
1997;35(11):1095–108.
21. Lamers LM, McDonnell J, Stalmeier PF, Krabbe PF, Busschbach JJ. The Dutch
tariff: results and arguments for an effective design for national EQ-5D
valuation studies. Health Econ. 2006;15(10):1121–32.
22. Cleemput I. Economic evaluation in renal transplantation: outcome
assessment and cost-utility of non-compliance. Leuven: Acco; 2003.
23. Greiner W, Weijnen T, Nieuwenhuizen M, Oppe S, Badia X, Busschbach J,
et al. A single European currency for EQ-5D health states. Results from a six-
country study. Eur J Health Econ. 2003;4(3):222–31.
24. Torrance GW. Social preferences for health states: an empirical evaluation of
three measurement techniques. Socio Econ Plan Sci. 1976;10(3):129–36.
25. S Acaster BP, J Osmond, C Mukuria. Mapping the Cystic Fibrosis
Questionnaire – Revised (CFQ-R) to a Preference Based Utility Index. 36th
European Cystic Fibrosis Society Conference 2013. 2013;June 12–15,
2013(Lisbon, Portugal).
26. Czyzewski DI, Mariotto MJ, Bartholomew LK, LeCompte SH, Sockrider MM.
Measurement of quality of well being in a child and adolescent cystic
fibrosis population. Med Care. 1994;32(9):965-72. PubMed PMID: 8090048.27. Powers PM, Gerstle R, Lapey A. Adolescents with cystic fibrosis: family
reports of adolescent healthrelated quality of life and forced expiratory
volume in one second. Pediatrics. 2001;107(5):E70. PubMed PMID: 11331720.
28. Abbott J, Dodd M, Webb AK. Different perceptions of disease severity and
self care between patients with cystic fibrosis, their close companions, and
physician. Thorax. 1995;50(7):794-6. PubMed PMID:7570419; PubMed Central
PMCID: PMC474657.
29. Quittner A, Suthoff E, Rendas-Baum R, Bayliss MS, Sermet-Gaudelus I,
Castiglione B, et al. Effect of ivacaftor treatment in patients with cystic
fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the
STRIVE randomized, controlled trial. Health Qual Life Outcomes. 2015;13:93.
30. Jedlicka-Köhler I, Götz M. Interventional assessment of physical and mental
health in children and adolescents with cystic fibrosis. Scand J Gastroenterol
Suppl. 1988;143:34-7. PubMed PMID: 3164507.
31. Charmaz K. Good days, bad days: The self and chronic illness in time.
Rutgers University Press; 1991
32. Moola F, Norman M. ‘Down the rabbit hole’: enhancing the transition process
for youth with cystic fibrosis and congenital heart disease by re‐imagining the
future and time. Child Care Health Dev. 2011;37(6):841–51.
33. Jessup M, Parkinson C. “All at sea”: The experience of living with cystic
fibrosis. Qual Health Res. 2010;20(3):352–64.
34. Brazier J, Rowen D. NICE DSU technical support document 11: alternatives
to EQ-5D for generating health state utility values. 2011.
35. Eidt-Koch D, Mittendorf T, Greiner W. Cross-sectional validity of the EQ-5D-Y
as a generic health outcome instrument in children and adolescents with
cystic fibrosis in Germany. BMC Pediatr. 2009;9:55.
36. Johnson JA, Connolly M, Zuberbuhler P, Brown NE. Health-related quality of
life for adults with cystic fibrosis: a regression approach to assessing the
impact of recombinant human DNase. Pharmacotherapy. 2000;20(10):1167–74.
37. Hennessy S, Kind P. Measuring health status in children: Developing and
testing a child-friendly version of EQ-5D. In: 19th Plenary Meeting of the
EuroQol Group: 2002; York, United Kingdom; 2002.
38. Wille N, Badia X, Bonsel G, Burstrom K, Cavrini G, Devlin N, et al.
Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual
Life Res. 2010;19(6):875–86.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
